MyMedicalRecords Receives Three Major Health IT Patents Expanding PHR Portfolio to Add Clinical Trials & Legal Records

LOS ANGELES, CA--(Marketwired - May 19, 2014) - MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, "MMR"), today announced that last week it received two Notices of Allowance ("NOA") and one issued patent for its health IT technologies from the United States Patent and Trademark Office. The first NOA is for U.S. Patent Application Serial No. 13/082,896, entitled "Electronic Health Records in Clinical Trials." The allowed application will be the first in a new family of patents directed toward using Personal Health Records ("PHRs") and other electronic forms of self-reporting to provide data in clinical trials, which has the potential to help save billions of dollars in costs of biopharmaceutical drug trials while also speeding up the trial process and helping to save lives.

According to MMRGlobal CEO Robert H. Lorsch, "The Company looks forward to our "896" clinical trials patent application opening the door to relationships with larger biotech companies who have been and continue to utilize various forms of Electronic Medical Records and PHRs in clinical trials and other patient monitoring systems. MMR's goal is to leverage its products and services and patents and other intellectual property to create working relationships with more companies in the biotechnology field so that patients and shareholders ultimately benefit."

The clinical trials patent will include 18 claims directed to methods and systems that provide for self-reporting being used to create Electronic Health Records for purposes including clinical trials. Self-reporting may be performed in various ways including via text message, through a website, by phone, or by fax, which are designed to help increase compliance and effectiveness of clinical trials while also reducing costs. The Electronic Health Records may also be created through various forms of telemedicine services directly from medical monitoring equipment associated with an individual. MMR is a practicing entity and a leading provider of secure and easy-to-use Personal Health Records through its MyMedicalRecords PHR, and MMRProPlus document management and imaging systems for healthcare professionals.

The second NOA granted to MMR is for Application Serial No. 13/663,101, entitled "Method and System for Providing Online Records," and will expand MMR's existing portfolio of eleven issued health IT patents with claims directed to the sharing of records with a second healthcare provider to better manage and facilitate second opinions. Additionally, MMR was recently issued U.S. Patent No. 8,725,537, entitled "Method and System for Providing Online Records," which is directed toward storing, managing and sharing legal records. This patent expands MMR's intellectual property beyond PHRs and other forms of Electronic Medical Records into the legal field. The '537 patent is particularly relevant to the management of wills and powers of attorney, among other similar types of important documents, which can be included as part of an individual's Personal Health Record account.

Adding clinical trials and legal records patents to MMR's patent portfolio has the potential of significantly increasing the value of the Company's intellectual property. Previous valuations did not include the value of patents specifically pertaining to clinical trials and/or legal information management.

In addition to Personal Health Record and other health IT products and services, MMR also offers MyEsafeDepositBox, which provides an online site to securely store important legal, financial, insurance and other important documents, as well as medical and personal health information.

MMR's global health information technology patent portfolio includes 11 U.S. patents: U.S. Patent Nos. 8,121,855; 8,117,045; 8,117,646; 8,301,466; 8,321,240; 8,352,287; 8,352,288; 8,498,883; 8,626,532; 8,645,161 and 8,725,537, which collectively include over 275 issued claims, along with additional applications and continuation applications pending. MMR has also received issued patents and has pending applications in 11 other countries or regional authorities of commercial interest including Australia, Canada, Singapore, New Zealand, Mexico, Hong Kong, China, Japan, South Korea, Israel, and Europe.

Although the MMR's primary business is as a provider and licensor of health IT products and services, the Company also has a portfolio of biotech patents. These pertain to cancer-fighting anti-CD20 monoclonal antibodies under the title, "Antibodies and Methods For Making and Using Them," issued in the U.S., Mexico, Australia and South Korea, with patents pending in the U.S., Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea, and additional patents pertaining to its B-cell idiotype vaccine worldwide.

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of MMR's products and services at Follow us at and

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, license, monetize and protect our patent portfolio for both MMR's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR's filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information:


Michael Selsman
Public Communications Co.
(310) 922-7033